Cetera Investment Advisers Acquires 110,386 Shares of Novo Nordisk A/S $NVO

Cetera Investment Advisers lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 38.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 396,557 shares of the company’s stock after buying an additional 110,386 shares during the quarter. Cetera Investment Advisers’ holdings in Novo Nordisk A/S were worth $14,573,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $28,000. Finally, Maseco LLP acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $50.89 on Wednesday. The company has a market cap of $227.22 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 4.53 and a beta of 0.77. The firm has a 50-day moving average of $46.60 and a 200-day moving average of $45.59. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.